Cello Health PLC - London-based healthcare consulting firm with experts in biotech and pharma strategy, healthcare market research, and medical communications - Gains shareholder approval on Monday for takeover by Value Demonstration UK Holdings Ltd, a company backed by Arsenal Capital Partners V LP and Arsenal Capital Partners V-B LP. Cello is to be bought for approximately GBP178.8 million and Cello shareholders will be entitled to receive 161 pence per Cello share.
Current stock price: 161.00 pence
Year-to-date change: up 20%
By Greg Roxburgh; email@example.com
Copyright 2020 Alliance News Limited. All Rights Reserved.